BioSpace News Archive

BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that the Cancer Center of Kansas (CCK) has been added as a new clinical trial site.

Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today reported results for the second quarter of 2018 and six-month period ended 30 June 2018. In addition, the Company has officially completed the change of name to Expedeon AG from SYGNIS AG.

The development of administrative tools for a standardized and centralized process increases access and positively impacts minority and high-risk populations.

Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter ended June 30, 2018.

MacroGenics, Inc.. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company’s management will provide a corporate overview presentation at the 2018 Wedbush PacGrow Healthcare Conference in New York on Tuesday, August 14, 2018 at 10:20 am (ET).

Families from Maryland, Virginia and Greater Washington D.C. Invited to Attend

According to a new review, approximately 30 million Americans - about 15 percent of adults - have chronic kidney disease, a number that is expected to increase in the next 20 years due to rising obesity rates and longer lifespans, but the majority of chronic kidney disease patients aren’t receiving potentially lifesaving treatment.

In July, 2018, I-Mab Biopharma (I-Mab) announced that it received clinical trial approval from China National Drug Administration (CNDA) for TJ103 (TG103) injection: an innovative, humanized, long-acting recombinant glucagon-like peptide-1 (hGLP-1) fused with a hybrid Fc (hyFc) for type 2 diabetes treatment

Top-line Superiority Data from NeoCart ® Phase 3 Clinical Trial on Track for Third Quarter of 2018

Ms. Bohlen is the chief operating officer of the Archdiocese of Chicago, where she oversees the organization’s administrative functions.